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infusion etc.). In measuring the number of tests conducted and time per test, i.e. labo-
ratory efﬁ ciency, we found that the use of regadenoson versus adenosine and dipyri-
damole could reduce the overall test time by 18 and 17 minutes respectively. Assuming
a baseline of 39 pharm-stress MPI tests per week for both adenosine and dipyridamole, 
the time saved per test using regadenoson translates into potentially servicing addi-
tional 330–366 patients per year. CONCLUSIONS: Due to its weight-independent
calculation and its administration via a rapid injection, the use of regadenoson may 
result in direct savings of laboratory personnel time and labor and the potential for 
increased patient throughput versus adenosine or dipyridamole. These time savings 
could lead to increased laboratory efﬁ ciencies (scheduling additional tests per week or 
reorganizing staff more efﬁ ciently).
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PREDICTED REDUCTION IN HOSPITAL DAYS AND ASSOCIATED COSTS
AMONG MANAGED CARE PRIMARY AND SECONDARY RISK MIXED
DYSLIPIDEMIA PATIENTS TREATED WITH FIXED DOSE NIACIN
EXTENDED-RELEASE AND SIMVASTATIN COMBINATION THERAPY
Simko RJ1, Balu S1, Webb SF1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA
OBJECTIVES: Compare predicted incremental reduction in hospital days and associ-
ated costs in managed health care (MHC) mixed dyslipidemia patient cohort treated 
with ﬁ xed-dose niacin extended-release and simvastatin (NERS) therapy. METHODS:
Two hypothetical formularies were modeled, a baseline formulary which did not 
include NERS and an adjusted formulary which did. Other lipid therapies included 
all marketed branded medications. The model was developed using product labeling,
clinical trial results, national prescription claims data, and a risk equation derived
from the HealthCore Integrated Research Database to estimate the incidence of car-
diovascular disease (CVD) events and associated hospital days avoided among patients 
achieving and not achieving optimal lipid values for LDL-C, HDL-C, and triglycerides 
(TG). Study patients included those aged q18 years with sub-optimal baseline LDL-C 
q 100 mg/dL, HDL-C a 40 mg/dL for males; a 50 mg/dL for females, and/or TG
levels q 150 mg/dL for females/diabetics; q 200 mg/dL for males/non-diabetics. A 
cost-effectiveness analysis was performed over three years evaluating the incremental
cost per hospital-day avoided after addition of NERS to current formulary. RESULTS:
Among 1,000,000 patients, 529,620 primary and secondary risk patients (52.96%) 
aged q 18 years were identiﬁ ed. Mean age at baseline was 54 o 11 years and 45%
was female. Over 3 years, there was reduction of 157 hospital days after addition
of NERS versus current formulary (54,839 vs. 54,997 days) along with a reduction
of $4,888,916 in total costs (sum of health plan costs, copayment, drug-monitoring 
costs, and CVD-event related costs) [$1,337,787,345 vs. $1,342,676,261], thus
achieving an incremental cost-saving of $31,041 per hospital day avoided. CONCLU-
SIONS: The MHC database-based model predicts that treating sub-optimal HDL-C 
and TG beyond achievement of optimal LDL-C goals may result in health care 
resource savings to a MHC organization after the addition of NERS to a managed
care formulary.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
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IMPACT OF MEDICATION ADHERENCE ON CARDIOVASCULAR
DISEASE-RELATED HEALTH CARE COST AMONG PATIENTS TREATED
WITH FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION 
THERAPIES AMONG DYSLIPIDEMIA PATIENTS IN A MANAGED CARE
POPULATION
Balu S1, Simko RJ1, Webb SF1, Yu J2, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA
OBJECTIVES: Assess the impact of optimal medication adherence on total cardiovas-
cular disease (CVD)-related total health care cost (THC) among dyslipidemia patients 
initiating ﬁ xed dose combination (FDC) therapy versus multi-pill combination (MPC) 
therapies in a managed care setting. METHODS: Study patients q 18 years were
identiﬁ ed as newly-initiating on FDC [Advicor: niacin extended release (NER) 
lovastatin] or MPC’s [simvastatin  NER (NER/S), lovastatin  NER (NER/L)] 
between January 1, 2000-June 30, 2006 [index date], with a minimum 6 months pre- 
and 12 months post-index health plan eligibility from a managed care database.
Multivariate generalized linear model was used to estimate association between opti-
mally adherent patients [Medication possession ratio (MPR) q 80%] and one-year
post-index CVD-related THC [sum of emergency room, inpatient, outpatient, and
medication costs] and sub-optimally adherent patients (MPR  80%) after controlling
for key demographic (age, gender) and clinical variables (FDC and MPC cohorts, 
comorbidity burden and number of non-dylipidemia medications). RESULTS: A total 
of 8988 patients (6638 FDC; 1687 NER/S; 663 NER/L) were identiﬁ ed. Those initiat-
ing FDC therapy were signiﬁ cantly younger [mean (SD) ages of 51.9 (10.5) vs. 56.0 
(9.8) years, p  0.0001] and had signiﬁ cantly lower baseline Deyo-Charlson comorbid-
ity scores (0.43 o 0.88 vs. 0.59 o 1.06; p  0.0001) versus MPC patients. At one year 
post-index, average MPR was higher among FDC patients versus both NER/S and
NER/L patients (0.54 o 0.35 vs. 0.50 o 0.35 and 0.47 o 0.34, respectively; p  0.01). 
After controlling for differences in baseline variables, multivariate regression showed
that patients with optimal adherence (MPR q 80%) had a 40% decrease in annual 
CVD-related THC versus sub-optimally adherent patients [Estimate: 0.601, 95% CI: 
0.427 – 0.845); p  0.003]. CONCLUSIONS: Optimal medication adherence among 
dyslipidemia managed care patients showed reduced CVD-related THC versus patients 
showing sub-optimal adherence. Further studies on early initiation of FDC therapy
targeting residual risk in dyslipidemia patients are warranted.
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RELATIONSHIP BETWEEN HEALTH LITERACY, OUTCOME
EXPECTATIONS, EFFICACY EXPECTATIONS AND MEDICATION
ADHERENCE
Bhor M1, Plake KS2, Chen JT2
1Abbott Laboratories, Abbott Park, IL, USA, 2Purdue University, West Lafayette, IN, USA
OBJECTIVES: The purpose of this study was to test the theoretical model of whether 
patient’s efﬁ cacy expectations and outcome expectations mediate the relationship 
between health literacy and medication adherence. In addition, the relationships 
between patients’ demographic variables and their health literacy skills, outcome 
expectations, efﬁ cacy expectations and medication adherence were evaluated
METHODS: A survey composed of four validated instruments along with questions
related to patient’s demographic information was utilized. The four validated instru-
ments assessed functional health literacy (S-TOFHLA), medication related outcome 
expectations and efﬁ cacy expectations and medication adherence (MARS). The 
questionnaire was pretested by conducting a pilot study of 21 patients with hyperten-
sion at a community health clinic. RESULTS: In the main study 200 patients with 
hypertension completed the self-administered survey. Path analysis was used to test
the theoretical model. Age had statistically signiﬁ cant associations with health literacy 
scores (ñ  0.17, p  0.015), efﬁ cacy expectations (ñ  0.23, p  0.004), and medica-
tion adherence (ñ  0.27, p  0.0001). In addition, number of prescriptions taken 
daily and insurance (t  5.30, p  0.001) had a statistically signiﬁ cant association
with medication adherence (ñ  0.16, p  0.024). Health literacy was only variable
that was statistically correlated with income (ñ  0.21, p  0.003) and level of educa-
tion (ñ  0.29, p  0.001). Path analysis indicated that medication adherence was sig-
niﬁ cantly associated with age and efﬁ cacy expectations, which also was related to 
health literacy level, age and income. Health literacy was also a signiﬁ cant predictor 
of outcome expectations. Gender, level of education, and income were the only demo-
graphic variables signiﬁ cantly associated with health literacy scores. CONCLUSIONS:
The results of the study suggested that health literacy had an impact on medication
adherence through efﬁ cacy expectations.
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EVALUATION OF AN EDUCATIONAL ANTIHYPERTENSIVE MEDICATION
ADHERENCE TOOL: IMPACT ON ANTIHYPERTENSIVE ADHERENCE AND
BLOOD PRESSURE CONTROL
Bui CN1, Hanson KA2, Prasla K1, Godley PJ1, Frech-Tamas F2, Rascati KL3
1Scott and White Health System, Temple, TX, USA, 2Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, USA, 3University of Texas at Austin, Austin, TX, USA
OBJECTIVES: Poor adherence to antihypertensive therapy increases patient risks 
of cardiovascular events. The objective of this study was to measure the effectiveness
of an individualized educational program on medication adherence and blood
pressure (BP) control. METHODS: This was a six-month, longitudinal study with a 
prospectively identiﬁ ed intervention group and a retrospective control group. The
Scott & White Health Plan enrollment and claim databases and EMR were utilized 
to identify continuously enrolled patients aged 18 years or older, diagnosed with 
hypertension, and treated with valsartan, aliskiren, or a ﬁ xed-dose combination of 
valsartan/hydrochlorothiazide or amlodipine/valsartan for at least three months 
prior to study enrollment. Patients meeting the inclusion criteria were invited to 
participate in the prospective intervention arm of the study, while those with geo-
graphic limitation served as controls. The intervention group received monthly per-
sonalized information about hypertension and treatment. A power analysis determined 
150 participants would be required in each arm to detect a 3% change in MPR. The 
intervention and control groups were matched based on demographic characteristics 
and Charlson Comorbidity Index score. All interval data were analyzed using paired 
t-tests, while categorical data were analyzed using chi-square tests. RESULTS: A
total of 159 patients enrolled into the study (60% female; mean [SD] age, 62 [12.6] 
years). Analysis of 95 matched patients showed no signiﬁ cant mean (SD) change in 
MPR (86% [0.2] to 83% [0.25] vs. 85% [0.24] to 82% [0.29]; P  0.8), systolic BP
(137.2 [15.1] to 136.3 [15] vs. 132.2 [14.8] to 136 [16.4] mmHg; P  0.2) and diastolic 
BP (72.6 [9.8] to 73.7 [13.1] vs. 72 [10.2] to 70.8 [10.5] mmHg; P  0.5) for the
intervention and control groups, respectively. CONCLUSIONS: Our pre liminary 
analysis showed no signiﬁ cant change in medication adherence and blood pressure. A 
complete analysis is necessary to determine the impact of the educational tool.
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HYPERTENSION: QUALITATIVE AND QUANTITATIVE SYSTEMATIC
REVIEW
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OBJECTIVES: The objective of this systematic review was to evaluate the impact of 
interventions to improve medication compliance in patients on antihypertensive medi-
cations. METHODS: CINAHL, EMBASE, all EBM Reviews and MEDLINE electronic
databases were searched for articles published January 1979 through February 2007
using MeSH keywords relevant to patient compliance and intervention type, yielding
A156 Abstracts
405 citations. Two reviewers independently examined each citation and abstract. We
conducted three levels of review resulting in 94 papers for full review. Data were
analyzed using qualitative and quantitative methods, including a meta-analysis using 
a random effects model (REM) and Mantel-Haenszel (MH) summary estimate.
RESULTS: The most common research design involved randomized controlled trials
(RCTs) (60/94, 64%). Seventy-two (77%) studies involved interventions that sought
to directly improve medication compliance, 12 (13%) had to do with interventions to
improve compliance through a multidisciplinary process, 5 (5%) involved interven-
tions to indirectly improve compliance through changing physician practice, and 5 
(5%) were other types. Thirteen studies (14%) involved the use of a theoretical 
framework to guide the research. A meta-analysis was conducted of RCTs of educa-
tional interventions, (N  6). The REM showed a trend toward statistical signiﬁ cance
with a risk ratio of 0.83 for non-compliance (95% CI: 0.68 1.00, p  0.05). The
MH summary estimate was statistically signiﬁ cant with a risk ratio of 0.83 for non-
compliance (95% CI: 0.75–0.92, p  0.00), favoring patients who received educational 
interventions to improve compliance. However, the X2 test for heterogeneity was sig-
niﬁ cant; p  0.020 and p  0.016 respectively. CONCLUSIONS: Our analysis indi-
cated that most interventions focused on directly improving medication compliance. 
The meta-analysis illustrated educational strategies provide a signiﬁ cant beneﬁ t in 
reducing non-compliance in patients using antihypertensives. The small sample size 
may have contributed to the observed heterogeneity and require additional investiga-
tion. Our ﬁ ndings have implications for designing future research and implementing 
educational interventions.
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MEDICATION ADHERENCE AND CARDIOVASCULAR DISEASE-RELATED
HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS TREATED
WITH FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION 
THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED 
CARE POPULATION
Balu S1, Simko RJ1, Webb SF1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA
OBJECTIVES: Evaluate the impact of medication adherence on total health care
resource utilization (THR) among dyslipidemia patients initiating ﬁ xed dose combina-
tion (FDC) therapy versus multi-pill combination (MPC) therapies in a managed care
population. METHODS: Using claims data from the HealthCore Integrated Research 
Database, study patients q18 years were identiﬁ ed as newly-initiating on FDC 
[Advicor: niacin extended release (NER)  lovastatin] or MPC’s [simvastatin  NER
(NER/S), lovastatin  NER (NER/L)] between January 1, 2000-June 30, 2006 [index 
date], with a minimum 6 months pre- and 12 months post-index health plan eligibility. 
Adherence was measured using medication possession ratio (MPR). Multivariate 
negative binomial regression was used to estimate association between study cohorts 
and one-year post-index cardiovascular disease (CVD)-related THR (sum of emer-
gency room, inpatient, and outpatient visits) after controlling for differences in base-
line age, gender, THR, Deyo-Charlson comorbidity index (DCI) score, number of 
non-dyslipidemia medications, and post-index adherence. RESULTS: Among study 
patients [8988 patients (6638 FDC; 1687 NER/S; 663 NER/L)], those initiating FDC 
therapy were signiﬁ cantly younger [mean (SD) ages of 51.9 (10.5) vs. 56.0 (9.8) years,
p  0.0001], comprised of fewer males (73.0% vs. 81.5%; p  0.0001), and had sig-
niﬁ cantly lower baseline DCI scores (0.43 o 0.88 vs. 0.59 o 1.06; p  0.0001) versus
MPC patients. During one-year follow-up, average MPR was higher among FDC
patients versus both NER/S and NER/L patients (0.54 o 0.35 vs. 0.50 o 0.35 and 0.47
o 0.34, respectively; p  0.01). Controlling for post-index adherence, multivariate
regression demonstrated that FDC patients had an 18% decrease in annual CVD-
related THR versus MPC patients [IRR: 0.819, 95% CI: 0.761–0.882); p  0.0001]. 
CONCLUSIONS: FDC-initiated patients showed improved medication adherence and
reduced CVD-related THR versus MPC-initiated patients in this managed care popula-
tion. Further studies on clinical and economic impact of improved adherence to FDC
dyslipidemia therapy are warranted.
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MEASURING THE IMPACT OF SOCIO-DEMOGRAPHIC
CHARACTERISTICS ON PATIENT PERSISTENCE IN CHRONIC MARKETS
Henderson SC1, Denarie MF2, Yuan Y1
1IMS Health, Blue Bell, PA, USA, 2IMS Health, Plymouth Meeting, PA, USA
OBJECTIVES: Although patient ﬁ nances are widely studied as predictors of adherence,
claims databases rarely include variables other than copay and insurance coverage.
Linking personal income, level of education, and ethnicity to prescription data can
enhance analyses of socioeconomic factors and adherence. We compared persistence 
in chronic markets – statins and oral antidiabetics (OADs) – by income, education, 
and ethnicity in linked administrative databases. METHODS: Using IMS’ LifeLink 
longitudinal prescription database (LRx), linked to commercial socio-economic data, 
we selected 143,370 patients initiating statins and 57,079 patients initiating OADs 
after a minimum 12 month clean period. LRx captures 62% of prescription claims
contributed by retail pharmacies in the US. Cox proportional hazards models compared
persistence by income, education, ethnicity, age, and method of payment. RESULTS:
Mean days of statin persistence was higher for patients with household income 
$75K/yr (149 days) than for patients with $40–75,000K/year household income
(144 days) (p  0.001). Patients with very low income ($K/yr) were more frequently 
on Medicaid or over age 65; these very low income patients had higher persistence
(150 days) than patients with income of $15$40,000/year (144 days) (p  0.005). 
Persistence also increased with level of education (graduate school  154 days vs. high 
school  147 days, p  0.001) and differed by ethnicity (Caucasian  150 days, Hispanic 
 127 days, African American  124 days; p  0.001). Similar trends were observed 
with OADs. CONCLUSIONS: Patients with higher household income demonstrate 
slightly improved persistence, while patients with very low income, but subsidized 
pharmacy beneﬁ ts, also have higher than average persistence. Differences in persistence 
also are found with higher levels of education and across ethnic groups.
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FRACTION OF NURSING HOME ADMISSION AND INCREMENTAL COST
ATTRIBUTABLE TO NON ADHERENCE TO ANTI HYPERTENSIVE 
MEDICATIONS
Rapp T, Schneider M, Zuckerman IH
University of Maryland, Baltimore, MD, USA
OBJECTIVES: We estimated the relationship between nursing home admission and 
non-adherence to anti-hypertensive medications. We calculated the incremental 
proportion of nursing home admission that was due to non-adherence, and the
annual incremental cost of the proportion of nursing home admission due to non-
adherence. METHODS: We calculated adherence scores in a cohort of 225,624 sub-
jects with hypertension from the MarketScan database. We used a generalized linear 
model with a binomial distribution and a log link to estimate adjusted relative risks
of nursing home admission. We calculated the fraction of nursing home admission
attributable to non-adherence. RESULTS: We showed that non-adherence to anti-
hypertensive medications increases the risk of nursing home admission. Among non-
adherent subjects, 10.8% were admitted to nursing homes. In the general population
of community-dwelling elderly subjects, 1.9% of nursing home admissions were 
attributable to non-adherence to anti-hypertensive medication. Extending these results
to the United States elderly (age q 65) population with hypertension, we found that 
annually 28,372 subjects were admitted to nursing homes in 2002 because of non-
adherence to anti-hypertensive medications. In 2002, the cost of nursing home admis-
sion due to non-adherence was estimated to be $1.7 billion. CONCLUSIONS:
Anti-hypertensive medication non-adherence was a risk factor for elderly transitioning
to long-term care facilities. Since non-adherence may be viewed as a proxy for lack 
of social support, our results show the potential beneﬁ ts related to interventions that
could provide social support to elderly patients, such as assistance with medication 
administration.
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FACTORS AFFECTING ADHERENCE TO ANTIHYPERTENSIVE
MEDICATION IN A NIGERIAN POPULATION
Ekwunife OI1, Aguwa CN1, Udeogaranya PO2
1University of Nigeria Nsukka, Nsukka, Enugu State, Nigeria, 2University of Nigeria Nsukka, 
Nsukka, Enugu, Nigeria
OBJECTIVES: Poor adherence to anti-hypertensives severely compromises the effec-
tiveness of treatment. The aim of this study was to measure adherence to antihyper-
tensive therapy and to determine the factors that are associated with poor adherence
in a sample of hypertensive patients in Nsukka, a semi urban town located in South-
Eastern Nigeria. METHODS: A cross sectional, household survey was conducted in
Nsukka. Adherence to antihypertensive medications was assessed on participants that
were hypertensive. Patient self-reports about the number of pills taken over a pre-
scribed period were used to estimate adherence as a percentage. In addition, Morisky 
Medication Adherence Scale (MMAS) was used in order to increase the strength and 
consistency of patient’s self-report on adherence. RESULTS: A total of 756 partici-
pants were screened for hypertension. Forty-seven persons were hypertensive. Mean 
adherence to hypertension medication was 70.7% o 37.9%. Mean adherence score 
was correlated to MMAS score (r  0.401, p  0.05). Educational status, making 
medications a habit, and experience of side effects were independently correlated to
adherence. Multiple linear regression showed that for every increase in educational 
status, adherence increased by 12.1%. Also making medication a habit increased 
adherence by 35.09%. However, experience of side-effect decreased adherence by
20.1%. CONCLUSIONS: These factors identiﬁ ed as correlates of adherence to anti-
hypertensives in the study population could be used to design interventions to improve 
adherence to hypertension medications in Nigeria.
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FLUSHING ASSESSMENT TOOL (FAST): PSYCHOMETRIC PROPERTIES
OF A NEW MEASURE ASSESSING FLUSHING SYMPTOMS
Kawata AK1, Thakkar R2, Davidson MH3, Punzi HA4, Jiang P2, Li D2, Krause S2, Padley R2, 
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OBJECTIVES: A common side effect of niacin therapy is ﬂ ushing characterized by 
warmth, redness, itching, and/or tingling. The FAST was developed to assess ﬂ ushing 
symptoms and clinical impact on patients. This study evaluated the psychometrics and
minimal important difference (MID) of the FAST. METHODS: A randomized, double-
blind, parallel group, multicenter, placebo (PBO)-controlled prospective 6-week study 
evaluated the FAST. 269 patients with dyslipidemia were randomized (1:1:1) to niacin 
extended-release (NER)/acetylsalicylic acid (ASA), NER/ASA PBO, or PBO/PBO. 
Patients completed the FAST electronic diary daily. RESULTS: FAST test-retest reli-
ability during the ﬁ rst 2 weeks among stable subjects was demonstrated for mean
overall ﬂ ushing severity using patient/physician-rated overall treatment effect (OTE) 
ratings (intraclass correlation coefﬁ cients of 0.75 and 0.76). Over the 6 week treatment
